相关实验视频

Updated: Jul 7, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

99m Tc标记循环针对PD-L1作为一种新型核成像探测器

Guillermina Ferro-Flores¹, Blanca Ocampo-García¹, Pedro Cruz-Nova¹

¹Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.

|December 23, 2023

概括

开发了一种新型的技术-99m标记的抑制剂,针对编程死亡配体1 (PD-L1),用于SPECT成像. 这种放射性药物在临床前模型和患者中成功检测到PD-L1阳性瘤,显示出癌症诊断的潜力.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射性药物化学放射性药物化学

背景情况:

癌症疗法越来越多地准瘤微环境免疫抑制,特别是编程死亡-1 (PD-1) 途径.
癌细胞通过表达PD-1连接体 (PD-L1) 来逃避免疫监测,PD-L1抑制了免疫T细胞.
准确的PD-L1表达的成像对于指导向免疫疗法至关重要.

研究的目的:

设计,合成和评估一种针对PD-L1 (Tc-iPD-L1) 的Tc标记循环抑制剂.
评估Tc-iPD-L1作为一种用于成像PD-L1表达在癌症中的SPECT放射性药物.
为了研究99mTc-iPD-L1.1的临床前和初始临床效用.

主要方法:

分子对接 (AutoDock) 用于对iPD-L1联体的亲和度计算.
化学合成涉及将一个循环与一种氨酸胺衍生物结合起来,然后进行99mTc标签.
进行了放射化学纯度 (Radio-HPLC),稳定性 (HPLC),特异性 (SDS-PAGE),细胞吸收,瘤携带小鼠的生物分布以及人类SPECT成像研究.

主要成果:

该iPD-L1连接体表现出高结合亲和力 (-6.7 kcal/mol),并以97%的纯度合成.
准备的Tc-iPD-L1具有90%以上的放射性化学纯度,并且在人体血清中表现出极好的稳定性 (>90%在24小时内).
试验室和体内研究显示了特定的PD-L1识别,高瘤吸收 (1小时6.98±0.89%的ID/g) 和快速清除.
在患有恶性黑色素瘤的患者中,SPECT成像成功可视化了PD-L1阳性病变.

结论:

99mTc-iPD-L1是一种有前途的SPECT放射性药物,用于成像PD-L1表达.
开发的药物在检测PD-L1阳性瘤方面表现出良好的临床前和临床初始性能.
需要进一步的剂量测量和临床研究来确定Tc-iPD-L1/SPECT成像的灵敏度和特异性.

关键词:

在PD-L1中.在PD-L1成像中使用PD-L1.这是一种PD-L1抑制剂.斯佩克特 (Spectre) 是一个运动场.技术-99m是一种

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

相关概念视频

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...